title: HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al.
authors: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d'Immunologie clinique, Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France.
authors: David
authors: D
authors: Saadoun
authors: AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d'Immunologie clinique, Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France.
authors: Patrice
authors: P
authors: Cacoub
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003449:Cryoglobulinemia / Q000188:drug therapy*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011480:Protease Inhibitors / Q000008:administration & dosage*; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011480:Protease Inhibitors; D011092:Polyethylene Glycols; D012254:Ribavirin
keywords: Rehabilitation; Rheumatoid Arthritis; Treatment